Previous Close | 32.15 |
Open | 32.73 |
Bid | 29.17 x 1400 |
Ask | 33.49 x 800 |
Day's Range | 31.26 - 34.20 |
52 Week Range | 10.00 - 35.37 |
Volume | |
Avg. Volume | 269,766 |
Market Cap | 875.519M |
Beta (5Y Monthly) | 1.74 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.69 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 36.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for TMDX
Suppose you invest in all three of these healthcare companies, and two of them go belly up. Here are our selections for biotech stocks that can run up 1,000% by 2027. George Budwell (Intellia Therapeutics): If you're on the hunt for a stock that can produce life-changing gains over the next five years, the beaten-down biotech industry is definitely a good place to start your search.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on June 1, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 35,000 shares of its common stock to three employees as a material inducement for each employee's entry into employment with TransMedics. The options were approved by the Compensation Committee o